Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07604233 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07604233: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07604233 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07604233, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
Interventions
- DRUG Venetoclax
- DRUG Fludarabine
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-11-30 |
| Est. Completion | 2033-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07604233
The ClinicalTrials.gov registry entry for NCT07604233 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Venetoclax is the first listed.
NCT07604233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07604233 about?
NCT07604233 is a clinical study titled "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML". The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
What is the current status of trial NCT07604233?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-11-30. Estimated completion is 2033-06-03.
What interventions are being tested in trial NCT07604233?
The interventions under investigation include: Venetoclax (DRUG), Fludarabine (DRUG), Cytarabine (DRUG), Idarubicin (DRUG), Filgrastim (DRUG).
Who is sponsoring clinical trial NCT07604233?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.